Robert J. Moccia
CEO, PreCision Dermatology and President, Onset Dermatologics
Mr. Moccia brings over 30 years of dermatology experience to Onset Dermatologics and PreCision Dermatology. Previously, he led Graceway Pharmaceuticals as its President and COO from its establishment in 2007 until its acquisition by Medicis Pharmaceuticals in 2011. Under his leadership, the company marketed the leading drug for the treatment of actinic keratosis and developed a robust pipeline of prescription dermatologic therapies. Formerly, Mr. Moccia was President of Chester Valley Pharmaceuticals, a company he co-founded, and President of Bioglan Pharmaceuticals. Through his career, Mr. Moccia also has held key positions at Medicis Pharmaceuticals and Dermik Laboratories. Mr. Moccia is an expert in creating customer-focused organizations that are widely admired for operational excellence and quality. His areas of expertise include strategy, drug development, licensing, marketing, and sales. Mr. Moccia holds a B.S. degree from Stonehill College.
Steven N. Tannenbaum
Executive Vice President and Chief Financial Officer
Mr. Tannenbaum brings more than 30 years of financial and operational experience to PreCision Dermatology. After serving as a tax professional with BDO Seidman and audit manager with Coopers & Lybrand (predecessor firm of PriceWaterhouseCoopers), he joined Copley Pharmaceutical Inc. (NASDAQ: CPLY), as Executive Vice President of Finance, CFO, Treasurer and Secretary. During his 10-year tenure at Copley, he was responsible for the Company’s financial, administrative, human resources, IT and supply chain activities. Mr. Tannenbaum also initiated and directed a number of private and public financings, including Copley’s initial and follow-on public offerings. Prior to his work at PreCision, Mr. Tannenbaum held senior financial corporate positions in a range of related industries. Mr. Tannenbaum earned a B.B.A. from Northeastern University and is a Certified Public Accountant.
Senior Vice President, Sales and Marketing, Onset Dermatologics
Mr. Havens comes to Onset Dermatologics from RKC Consulting, a firm that he founded to help dermatology clients develop strategic plans and assess opportunities to grow their businesses. Mr. Havens served as Executive Vice President of Sales & Marketing at Medicis Pharmaceuticals, Inc. from 1998 until 2008. In this capacity, Mr. Havens developed strategies and executed plans in both medical and aesthetic dermatology that helped build the company into a leading player in the dermatology space. Prior to joining Medicis, Mr. Havens led global Business Development efforts as Executive Director (1995-1998) and served as Director of Marketing (1988-1992) for Dermik Laboratories. Mr. Havens’ global experience also includes serving as Vice President of Sales and Marketing for Rhone Poulenc Rorer, Canada.
Martin Redmon, Ph.D.
Senior Vice President, Research, Development and Technical Operations
Dr. Redmon has more than 20 years of experience in pharmaceutical R&D, operations, and project and functional line management. Prior to joining PreCision, he served as Vice President of Operations at ArQule, Inc., where he led a broad range of functions, including chemical process R&D and drug product development focused on taking small molecule kinase inhibitors from late discovery through commercial-scale production. Previously, Dr. Redmon held pharmaceutical development positions with increasing levels of responsibility at Eli Lilly and Co., Focal, Sepracor, and Praecis. In those roles, he managed development of a broad range of dosage forms, including large molecule sterile injectables, oral solids, polymeric delivery devices, and inhalation aerosols, for a number of therapeutic applications (e.g., diabetes, allergy/asthma, surgical devices, and oncology). He holds a B.S. in Chemical Engineering and Ph.D. in Pharmaceutical Sciences both from the University of Kentucky.